Xerostomia Therapeutics Market Size, Share & Trends Analysis Report By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global xerostomia therapeutics market size was estimated at USD 2.0 billion in 2022 and it is anticipated to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2030. The increasing adoption of chemotherapy and radiotherapy in cancer treatment coupled with the growing use of prescribed medications are among the key factors expected to boost the market growth.

Xerostomia refers to a condition of oral dryness mainly caused by reduced saliva production. This condition may lead to a sensation of dryness in the mouth, oral burning, difficulty in swallowing, and reduction or loss of taste. Chemotherapy and radiation damage the salivary gland and cause dry mouth. Chemotherapy is the most common form of treatment for cancer patients provided by oncologists and medical practitioners. Xerostomia is usually a side effect of medication, head & neck radiation therapy, and chemotherapy, and it may also be caused due to Sjogren’s syndrome. The American Cancer Society estimates that 3.5 million women live with breast cancer in the U.S., as of January 1, 2016. Among women with stage IV breast cancer, 48% receive radiation and/or chemotherapy.

The easy availability of cost-effective medications is one of the key drivers of the market. Products include sugar-free gum, lozenges, toothpaste, oral-adhering discs, patches, and melts, as well as oral rinses. These products have reasonable reimbursement policies and have a price range of USD 10 to USD 90. For instance, the Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia undergoing treatment with the drug, Salagen, under the Exceptional Access Program (EAP). An increase in the use of prescription medications is expected to positively affect the market growth. According to the National Institute of Dental and Craniofacial Research, more than 400 medications may cause xerostomia.

Prescription medicines such as antidepressants, antihypertensives, sedatives, antiparkinson, antiemetics, and antipsychotics affect the salivary gland and cause xerostomia. The increasing prevalence of diseases such as Parkinson’s disease, hypertension, and diabetes leads to the use of prescription drugs, thus causing the condition of dry mouth.

Type Insights

Based on type, the market is categorized into Over-the-Counter (OTC) and prescription segments. The OTC segment held the largest market share in 2022 and is expected to grow at a lucrative CAGR of 3.3% over the forecast period. The dominance is owing to its wide variety & availability, safety & efficacy, availability of limited branded drugs, and low pricing of products. OTC products are the first-line treatment for xerostomia. Most xerostomia can be dealt with OTC products without any complications. In severe cases, prescription drugs are utilized. With proper care and medication, it can be managed and controlled and any further complications can be avoided.

Product Insights

Based on product, the market is categorized into salivary stimulants, salivary substitutes, and dentifrices. The salivary stimulants segment dominated the market in 2022 with a share of 35.9%. Salivary stimulants are substances that can increase the production of saliva. They can be further classified as pharmacological (acts on the nervous system) and non-pharmacological (acts on taste buds or chewing muscles). They are available in various forms such as mints, sugar-free chewing gums, sprays, and lozenges. In November 2018, 3M launched Xerostomia Relief Spray, which relieves the mouth for up to 4 hours by moistening and lubricating mucosa. In September 2021, ICPA Health Products Ltd., launched Wet Mouth, a sodium carboxymethyl cellulose-based saliva substitute for treating xerostomia, which helps reduce surface abrasion.

The dentifrices segment is expected to grow at the fastest CAGR of 4.9% over the forecast period. These are special teeth cleaning agents, powders, or pastes, which help in reducing dry mouth by excluding irritants causing dry mouth. GC America Inc.’s MI Paste and MI Paste Plus are products that can be applied to the teeth to help stimulate saliva production as well as restore healthy components of saliva such as calcium and phosphate.

Regional Insights

North America dominated the market in 2022 with a revenue share of 39.9%. Key factors contributing toward dominance are the increasing prevalence of xerostomia and other dry mouth-associated diseases such as Sjogren’s syndrome, and rheumatoid arthritis, coupled with an increase in dry mouth awareness initiatives. The Sjogren’s Foundation has taken initiatives to spread awareness of Sjogren’s syndrome by creating the April is Sjogren’s Awareness Month campaign.

Asia Pacific is anticipated to grow at the fastest CAGR of 5.0% over the forecast period due to rising healthcare spending, an increase in awareness-raising campaigns, and an increase in the prevalence of diabetes, cancer, and Parkinson's disease. According to a study by NIH, the incidences of Parkinson’s disease increased by 202.22%, 204.06%, 164.21%, and 67.93% in East Asia, South Asia, Southeast Asia, and Central Asia, respectively, from 1990 to 2019.

Key Companies & Market Share Insights

Key players focus on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. As per the article published in June 2023, MeiraGTx, a clinical-stage gene therapy company, is developing AAV-AQP1, which is in phase II for the treatment of xerostomia. It is for xerostomia treatment caused by the use of ionizing radiation in the treatment of neck & head cancer and Sjogren's syndrome-related xerostomia. Some prominent players in the global xerostomia therapeutics market include:

• GlaxoSmithKline plc

• Church & Dwight Co., Inc.

• Colgate-Palmolive Company

• Hikma Pharmaceuticals PLC

• Pendopharm

• Sun Pharmaceuticals Industries Ltd.

• Lupin Pharmaceuticals, Inc.

• Pfizer, Inc.

• Parnell Pharmaceuticals, Inc.

• Acacia Pharma

• OraCoat

Xerostomia Therapeutics MarketReport Scope

Global Xerostomia Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global xerostomia therapeutics market report based on product, type, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • OTC

  • Prescription

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Salivary Stimulants

  • Salivary Substitutes

  • Dentifrices

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait